background_1 background_2

Emplois / Jobs

Postdoctoral position available in France in the teams of Marc DALOD, at Centre
d’Immunologie de Marseille-Luminy, Marseille, & Nicolas Manel, at Institut Curie, Paris.

Deadline for application: September 15th 2017.
Starting date: February 1st 2018
Title of the research program: Deciphering the molecular regulation of the differential
interaction of human dendritic cells with HIV.
Scientific background for the project:
Vertebrate resistance to viruses relies on both innate and adaptive immunity. Dendritic cells (DC)
play a crucial role in this process. They are able to sense infections to initiate innate immune
responses, and then to orchestrate the transition towards the activation of adaptive immunity. DC
constitute a heterogeneous cell population, defined by distinct cell types endowed with different
functions. DC are pivotal targets of HIV due to their critical ability to regulate the immune response.
Knowledge on the functional specialization of DC types and its molecular regulation is still largely
incomplete, especially in the context of HIV infection. We have recently discovered that distinct DC
types are functionally specialized for HIV infection. In particular, we have uncovered that DC1
(CD141+XCR1+) are constitutively resistant to infection by HIV and several other enveloped viruses.
This creates a 'division of antiviral labor' across DC and results in a cooperation between DC types
to activate adaptive immunity. The goal of the project is to discover the molecular mechanisms that
enable the division of labor and the DC cooperation for antiviral immune responses.
Specific objectives of the research program:
The applicant will use in vitro models of human DC types to decipher the role of candidate genes in
the control of the differential antiviral resistance across DC subsets. In addition, the applicant will
develop new cellular in vitro models of DC to overcome current limitations in the experimental study
of DC types.
Environment: The teams belong to an Excellency Laboratory (DC-BIOL Labex) headed by Sébastian
Amigorena (Curie) and Bernard Malissen (Marseille). The applicant will benefit from strong
collaborations within the Labex DC-BIOL and with several Institutes abroad. The project will be
performed in close collaboration between the laboratories of Marc Dalod (CIML) and Nicolas Manel
(Institut Curie). The applicant will be hosted at the most appropriate location, based on previous
experience of the candidate and personal constraints.
The applicant will benefit from highly collaborative environments and state-of-the-art technological
platforms. Institut Curie is located in the center of Paris in a culturally and scientifically rich
environment. CIML is located on the Luminy campus regrouping fundamental research laboratories
in all disciplines of life sciences, in informatics, physics, chemistry and mathematics, and biotech
start-up companies, including several that emerged from CIML work: Immunotech, Innate Pharma,
Oz Bioscience and HalioDx.
Applicant profile: The applicant must have a Ph.D. in Virology and a documented positive experience
in studying retroviruses or using lentivectors, or a Ph.D. in Immunology and a document positive
experience in studying human immune cells in vitro. Excellent communication skills and team spirit
are essential.
Contact: Please send applications by e-mail to dalod@ciml.univ-mrs.fr and nicolas.manel@curie.fr,
including i) a curriculum vitae with a brief summary of professional experience, education, key
qualifications, awards, and the name of 2 referees with their contact information, ii) a complete list
of publications, and iii) a motivation letter.
References:
Silvin et al., Science Immunology 2017. doi: 10.1126/sciimmunol.aai8071 .
Gentili et al., Science 2015. doi: 10.1126/science.aab3628 .
Balan et al., J Immunol 2014. doi: 10.4049/jimmunol.1401243 .




2-YEAR POST-DOCTORAL POSITION OPEN IN TUMOUR IMMUNOLOGY IN LYON, FRANCE

Role of type III interferon and myeloid dendritic cells in anti-tumor immune responses
Project: The aim of the team is to identify mechanisms involved in immune subversion by cancer cells and to develop therapeutic strategies based on the reactivation of immune-surveillance. It is well known in mice that a population of dendritic cells (DC) named CD8a/ XCR1+ DC is key in the establishment of an effective anti-tumor immune response, and more particularly during immune checkpoint therapies. This DC population produce high level of type III interferon in response to TLR3 ligand stimulation. The aim of the present project is to understand in human the role of this DC population in breast and ovarian cancer and the regulation of type III interferons in the tumor microenvironment. This new type of IFN which is related to type I interferons may have an important role in activating the adaptive anti-tumor immune response. The candidate will also explore transcriptomic data analysis done on tumor infiltrating XCR1+ DC that are currently being generated, in order to identify new molecular pathways modified by the tumor microenvironment. Finally, the candidate will analyze the correlation between XCR1+ DC infiltration in tumors and the prognosis of patients by working on retrospective cohorts of breast tumors (in close collaboration with the biopathology department of the Centre Léon Bérard).
This project will benefit from access to tumors samples (breast and ovarian cancers) and human tonsils and blood from healthy volunteers. Techniques used are immunohistology and immunofluorescence, flow cytometry, ELISPOT, ELISA and qPCR. The candidate will benefit from CRCL core facilities.
Team and location: “Therapeutic targeting of the tumor cells and of their immune stroma ». Co-directors : Christophe CAUX and Jean Yves BLAY at the Cancer Research Center of Lyon in Centre Léon Bérard, Lyon, FRANCE (www.crcl.fr).
Supervisor : Jenny VALLADEAU-GUILEMOND, PhD, CR1 INSERM, HDR.
Publications : . Balan S. et al., J Immunol. 2015; Deauvieau F. et al., Int J Cancer. 2015; Segura et al., J Exp Med 2012; Verronèse E. et al., OncoImmunology 2015
Funding: The contract is for 2 years and funded by The LabeX DEVweCAN.
Candidate : We are looking for motivated PhD or an MD-PhD with experience in anti-tumour immunity. They must have a strong interest in onco-immunology and possibly with a previous experience in this field. Skills in flow cytometry, cell culture, and histology will be valued.  
Applications must include a CV with a cover letter and contacts for 2 references. Please submit applications to: jenny.valladeau-guilemond@lyon.unicancer.fr.




Post-doctoral Positions at the Institut Pasteur de Lille

CIIL, Inserm U1019-CNRS UMR 8204
Institut Pasteur de Lille
1, rue du Pr Calmette, BP 245
59019 Lille Cedex, France

1
Postdoctoral position available in the “Nods-like receptors in
infection and immunity
” Group at the Institut Pasteur de Lille
The Chamaillard lab is recruiting a three-year postdoctoral fellow to study how the
circadian rhythm regulates epithelial regeneration and epithelial carcinogenesis
. The
focus of the lab is on the impact of the microbiota on epithelial carcinogenesis (J Clin
Invest. 2013 Feb;123(2):700-11 and Nat Cell Biol. 2015 Aug;17(8):1062-73) and anticancer
drugs efficacy (Science. 2015 Nov 27;350(6264):1079-84 and Immunity In
press).
Enthusiastic and autonomous applicants of any nationality must hold a PhD in
oncology or epithelial cell biology with a strong interest on host-microbiota
interactions. Experience in handling laboratory mice and good skills in organoid
cultures will be of advantage. Fluent knowledge of English, high level of motivation for
scientific work and excellent communication skills are expected.
Candidates are encouraged to submit a motivation letter, a CV and two references
letters to mathias.chamaillard@inserm.fr by November 11th, 2016.
Closing date: 2016-11-11
Interviews of candidates: 2016-11-14 to 18
Expected employment starting date: 2017-02-01.

2
Postdoctoral position available in the “Nods-like receptors in
infection and immunity
” Group at the Institut Pasteur de Lille
The Chamaillard lab is recruiting a three-year postdoctoral fellow to study how the
epithelial barrier coordinates the oscillatory behavior of the gut microbiota and how
the microbiota modulates the efficacy of chronomodulated anti-cancer drugs
therapies
. The focus of the lab is on the impact of the microbiota on epithelial
carcinogenesis (J Clin Invest. 2013 Feb;123(2):700-11 and Nat Cell Biol. 2015
Aug;17(8):1062-73) and anti-cancer drugs efficacy (Science. 2015 Nov
27;350(6264):1079-84 and Immunity In press).
Enthusiastic and autonomous applicants of any nationality must hold a PhD in
oncology or epithelial cell biology with a strong interest on host-microbiota
interactions. Experience in handling laboratory mice and good skills in metagenomics
will be of advantage. Fluent knowledge of English, high level of motivation for
scientific work and excellent communication skills are expected.
Candidates are encouraged to submit a motivation letter, a CV and two references
letters to mathias.chamaillard@inserm.fr by November 11th, 2016.
Closing date: 2016-11-11
Interviews of candidates: 2016-11-14 to 18
Expected employment starting date: 2017-02-01.





Post-doctoral Positions

Laboratory of Jose Villadangos
Peter Doherty Institute of Infection and Immunity
The University of Melbourne, Australia


upload_fichiers/1465891276-pd-position-dc-jvl-2016.pdf

upload_fichiers/1465891268-pd-position-act-jvl-2016.pdf